Mandric 2009.

Methods	Unclear (possibly a CCT)
Participants	27 children aged between 3 and 18 years Enalapril group: 10 children with subclinical cardiotoxicity on echocardiography No "cardioprotector" group: 6 children with a chemotherapeutic protocol completed. It was not specified if this group suffered from cardiotoxicity. Newly diagnosed group: 11 children with newly diagnosed cancer. It was not specified if this group received an intervention. No further participant characteristics were provided. Duration of follow‐up was unclear
Interventions	Enalapril (not further specified) No "cardioprotector" (not further specified)
Outcomes	Periodic history and physical examination, electrocardiogram, chest X‐ray, 2‐dimensional/Doppler echocardiography, cardiac biomarkers (BNP, cTnI, ALAT, CPK). "Clinical manifestations": heart failure: 1 participant; "untypical manifestation": 15 participants; "echocardiographic modifications": 6 participants; electrocardiographic changes: 5 participants; high values of plasma BNP (cutoff value of 100 microgram/ml): 11 participants. The differences in these outcomes between subgroups were not mentioned, except that all children on "cardioprotector" treatment had normal values of BNP and cTnI
Notes	This study has not been published in full text, but was presented at the SIOP conference 2009 (abstract PQ.020). The title suggested that cardiotoxicity in children in the "no cardioprotector group" (and possibly also in the "newly diagnosed group") was caused by anthracyclines. It seems that participants were not randomised. Completeness of follow‐up was not mentioned

ALAT: alanine transaminase
 BNP: brain natriuretic peptide
 CCT: controlled clinical trial
 CPK: creatine phosphokinase
 cTnI: cardiac troponin I
 LV: left ventricular
 SIOP: Société Internationale d'Oncologie Pédiatrique (International Society of Paediatric Oncology)